How Quickly Does Paget’s Disease of the Breast Progress?

Paget’s disease of the breast has no single, predictable timeline. The visible skin changes on the nipple often develop slowly over months, sometimes years, giving the impression of a sluggish condition. But the skin is only the surface of the story: more than 90% of cases have an underlying breast cancer already in place at the time of diagnosis, and the biology of that cancer, not the pace of the rash, determines how fast things actually move. Some cases remain confined as non-invasive disease for years; others harbor aggressive tumors that can spread quickly, particularly when driven by certain molecular features.

Why the Skin Changes Seem So Slow

The most visible part of Paget’s disease is an eczema-like change on the nipple or the surrounding areola. It usually starts with redness, scaling, or a crusty patch that looks like dry skin or mild dermatitis. Over weeks or months it can progress to oozing, itching, or flattening of the nipple. Because these changes resemble common, harmless skin conditions, many people (and their doctors) initially treat them with moisturizers or steroid creams and wait to see if they resolve.

This resemblance to benign skin problems is the main reason Paget’s disease appears to progress slowly. The condition itself may have been present for a long time before anyone suspects cancer. A systematic review of cases initially misdiagnosed as other skin conditions found that the average delay from first symptoms to correct diagnosis was about 2.3 years, with the shortest delay being a single week and the longest stretching to a full decade.¹ The disease is not necessarily moving slowly during that time. It is being overlooked.

Common misdiagnoses include eczema, atopic dermatitis, psoriasis, and even other skin cancers like squamous cell or basal cell carcinoma.² The critical red flag is that the changes are unilateral, affecting only one nipple. Eczema on both nipples might reasonably be treated as a skin condition; a persistent, scaly, oozing rash on one nipple that does not respond to topical treatment should raise suspicion and prompt a biopsy.

The Underlying Cancer That Sets the Real Pace

Paget’s disease of the nipple is not just a skin problem. More than 90% of cases are associated with an underlying breast malignancy, most often ductal carcinoma in situ (DCIS) in the milk ducts beneath the nipple, and sometimes invasive breast cancer located elsewhere in the breast, even more than two centimeters away from the nipple itself.³ This is the part of the disease that truly dictates how fast it progresses and how dangerous it becomes.

How Paget cells end up in the nipple skin remains debated. The prevailing explanation is that cancer cells from the underlying breast tissue migrate outward along the milk ducts until they reach the nipple surface. An alternative theory holds that the malignant cells arise independently within the nipple skin itself, which would explain the minority of cases where no underlying tumor is found.⁴ Regardless of the origin story, the practical implication is the same: a rash on the nipple is usually the visible signal of a cancer deeper inside.

When the underlying cancer is purely DCIS, the disease can remain non-invasive for a prolonged period. DCIS by definition has not broken through the walls of the milk ducts, and many patients with Paget’s disease associated only with DCIS have excellent long-term outcomes. But when the underlying cancer is invasive, meaning it has spread beyond the ducts into the surrounding breast tissue, the progression risk jumps substantially.

The Palpable Mass Divide

If there is one clinical factor that separates slow-moving Paget’s disease from fast-moving Paget’s disease, it is whether you can feel a lump in the breast. This distinction has been consistent across studies for decades, and the survival gap is dramatic.

One study of 31 patients found that those without a palpable mass had a five-year overall survival of 94%, while those with a palpable mass had a five-year survival of just 19%.⁵ A larger meta-analysis confirmed the pattern: patients with palpable tumors had significantly worse prognoses in terms of metastasis than those with impalpable disease.⁶ Another study identified both a palpable mass and a suspicious mammogram as risk factors for worse survival, and the combination of both carried the poorest outlook.⁷

The logic is straightforward. A palpable mass usually means the cancer has grown large enough or invasive enough to form a detectable lump, which correlates with more advanced disease at diagnosis. Paget’s disease caught at the “skin changes only” stage, before any lump develops, has a fundamentally different prognosis from the same disease caught later. This is why the question “how fast does it progress” often comes down to “how early was it found.”

HER2 and Why Some Cases Move Faster

Paget’s disease of the breast has a distinctive molecular profile compared to ordinary breast cancer. A large population-based study found that tumors associated with Paget’s disease had substantially higher rates of HER2 overexpression, around 52.5%, compared to roughly 15% in standard invasive ductal carcinoma.⁸ HER2-positive cancers tend to be more aggressive if untreated, growing and spreading faster than HER2-negative types. The same study found that the estrogen-receptor-negative, HER2-positive subtype was six times more common in Paget’s disease cases than in regular breast cancer.

This HER2 enrichment helps explain why some Paget’s cases seem to move quickly after diagnosis. A case report documented a patient with Paget’s disease and underlying DCIS who developed metastases rapidly after surgery, a scenario not typically expected with DCIS alone. The authors concluded that HER2-positive status likely drove the aggressive behavior and recommended early postoperative imaging and close follow-up for such patients.⁹

The flip side is that HER2-positive status also opens the door to targeted therapies. In one case of relapsed Paget’s disease, treatment with trastuzumab emtansine (a HER2-targeting drug) successfully resolved the skin symptoms.¹⁰ So while HER2 overexpression can drive faster progression, it also provides a therapeutic target that did not exist a couple of decades ago.

How Imaging Reveals What the Skin Does Not

Because the skin changes in Paget’s disease can appear deceptively mild, imaging plays a critical role in understanding how far the disease has actually progressed. The tricky part is that standard mammography can appear completely normal in a significant number of Paget’s cases, especially when there is no associated mass or calcifications.

MRI has become increasingly important for these patients. It is highly sensitive and can detect abnormalities even when both mammography and ultrasound come back clean.¹¹ In one study of nine patients with confirmed Paget’s disease, MRI detected abnormal nipple enhancement in eight, and also picked up DCIS elsewhere in the breast (away from the nipple) in four of the nine patients.¹² Finding cancer at a distance from the nipple changes the entire treatment plan and gives a more realistic picture of how far things have gone.

The practical takeaway is that a normal mammogram does not rule out significant disease in someone with nipple changes consistent with Paget’s. If the clinical suspicion is there, MRI can catch what other imaging misses, and what it finds may dramatically alter the assessment of how advanced the cancer really is.

Treatment Choices and Local Recurrence

Historically, mastectomy was considered the default treatment for Paget’s disease. The rationale was that the disease might extend through the duct system in ways that breast-conserving surgery could miss. But the evidence has shifted considerably, and the picture is now more nuanced.

A meta-analysis comparing the two approaches found that breast-conserving surgery had a higher local recurrence rate (about 13%) than mastectomy (about 6%).¹³ That gap narrows when radiation therapy is added after breast-conserving surgery, particularly in patients whose underlying pathology is DCIS rather than invasive cancer.¹⁴ A long-term study of breast-conserving surgery with radiation reported local control rates of 91% at five years and 87% at ten years, supporting this approach as a viable alternative to mastectomy for patients without a palpable mass.¹⁵

When it comes to actual survival rather than local recurrence alone, a large population-based analysis using propensity matching found no significant survival advantage for mastectomy over breast-conserving surgery. Five-year breast-cancer-specific survival was about 96% after breast-conserving surgery and 94% after mastectomy, and the difference did not reach statistical significance at ten years either.¹⁶ The choice between the two depends on the extent of disease, the patient’s anatomy and preferences, and whether the underlying cancer is invasive.

When recurrence does happen after surgery, it does not necessarily come quickly. One review of cases after nipple-sparing mastectomy found that the average time from surgery to local recurrence of Paget’s disease was about 40 months.¹⁷ Another study with a median follow-up of about six years found a recurrence rate of roughly 15%, with younger age and the type of surgery influencing recurrence risk.¹⁸ Long-term surveillance matters regardless of which surgical approach is chosen.

Paget’s Disease in Men

Men can develop Paget’s disease of the breast, though it is rare. The disease tends to carry a worse prognosis in men, with five-year survival rates historically reported in the range of 20 to 30%, compared to 30 to 40% in women.¹⁹ The smaller size of the male breast is thought to contribute to this disparity: with less tissue between the skin and the chest wall, local extension and involvement of the lymph nodes can happen earlier.

Men also face additional diagnostic delay because breast cancer in general is not on most people’s radar for male patients. A scaly nipple in a man is even less likely to prompt an immediate biopsy than in a woman, and by the time the diagnosis is made, the disease may be more advanced. The same principles apply, though: early detection, before a mass forms, is the single most important factor in outcome.

Extramammary Paget’s Disease

Paget’s disease is not exclusive to the breast. An extramammary form appears in areas with a high density of apocrine sweat glands, most commonly the vulva, perianal region, groin, or axillae. It presents as reddish, scaly plaques that can look like a chronic rash or fungal infection. While mammary Paget’s disease is almost always associated with an underlying breast cancer, the extramammary version has a much less consistent link to internal malignancies.²⁰

Extramammary Paget’s disease tends to progress even more slowly than the breast version when no underlying cancer is present. It can persist for years as a superficial skin condition. However, when it is associated with an internal malignancy (such as colorectal or genitourinary cancer), the prognosis depends entirely on that underlying cancer.²¹ The conditions share a name and some histological features but behave quite differently in practice, and a diagnosis of one does not imply the same risk profile as the other.

What “Progression” Really Means for This Disease

Asking how quickly Paget’s disease progresses is a bit like asking how fast a car goes without specifying the engine. The skin changes themselves can evolve over months to years and tend to remain localized to the nipple-areola region for a long time. But the clinically meaningful progression, the part that determines whether the disease is life-threatening, happens beneath the surface in the underlying breast tissue.

For someone whose Paget’s disease is caught early, with no palpable mass, no invasive cancer on imaging, and DCIS as the only underlying finding, the prognosis is genuinely excellent. Five-year survival rates well above 90% are consistent across multiple studies, whether treated with mastectomy or breast-conserving surgery plus radiation. For someone whose disease has progressed to invasive cancer with a palpable mass, especially with HER2-positive biology and lymph node involvement, the outlook is far more guarded, and systemic treatment becomes essential.

The single most actionable piece of knowledge for anyone worried about this disease is that a persistent, unilateral nipple change that does not respond to topical treatment within a few weeks deserves a biopsy, not another course of steroid cream. The evidence overwhelmingly shows that outcomes hinge on whether the disease is caught before or after it becomes invasive, and the diagnostic delay data suggests that many cases are caught later than they need to be. You cannot control how fast the biology moves, but you can control how fast you get it evaluated.